Trails Edge Capital Partners »

Cytokinetics shares owned by Trails Edge Capital Partners

Quarter-by-quarter ownership of Cytokinetics (CYTK) shares owned by Trails Edge Capital Partners from 13F filings

Historical chart of Trails Edge Capital Partners investment in Cytokinetics

Tip: Access up to 7 years of quarterly data

All positions including Cytokinetics held by Trails Edge Capital Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Cytokinetics by Trails Edge Capital Partners

Quarter filed Position value Share count Share price at filing
2026-03-31 $20M 300k 65.91

More positions owned by Trails Edge Capital Partners

Vaxcyte (PCVX)
Xenon Pharmaceuticals (XENE)
Definium Therapeutics Com Shs (DFTX)
Lb Pharmaceuticals Com Shs (LBRX)
Mirum Pharmaceuticals (MIRM)
Nurix Therapeutics (NRIX)
Revolution Medicines (RVMD)
Arcus Biosciences Incorporated (RCUS)
Immunocore Hldgs Ads (IMCR)
Cytokinetics Com New (CYTK)
Syndax Pharmaceuticals (SNDX)
Neurogene (NGNE)
Inventiva Sa Ads (IVA)
Inhibikase Therapeutics Com New (IKT)
4d Molecular Therapeutics In (FDMT)

View all positions for Trails Edge Capital Partners

Top funds holding Cytokinetics

T. Rowe Price Investment Management
BlackRock
FMR
Vanguard Group
Wellington Management Company
Vanguard Portfolio Management
State Street Corporation
Vanguard Capital Management
Geode Capital Management
Bank of America Corporation
Susquehanna International
Rtw Investments
Armistice Capital
Goldman Sachs Group
Polar Capital Holdings

View all funds holding Cytokinetics